Inactive Instrument

Vifor Pharma

VIFN

CH0364749348

Vifor Pharma AG Provides Earnings Guidance for the Fiscals Year 2019 and 2020

August 08, 2019 at 10:30 am IST

Vifor Pharma AG provided earnings guidance for the fiscals year 2019 and 2020. For the fiscal year 2019, at constant exchange rates, net sales are expected to exceed 15%. In 2020 net sales are expected to exceed CHF 2 billion.

Latest news about Vifor Pharma

European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	19/04	MT
CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	02/23/02	CI
Court Cancels Public Shares of Vifor Pharma after Merger with CSL	14/22/14	MT
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	03/22/03	MT
Australia's CSL raises annual profit forecast on Swiss acquisition	17/22/17	RE
Global markets live: Darktrace, Intel, Twitter, Meta, Uber...	12/22/12
Vifor Pharma Gets Approval To Delist From Swiss Bourse	12/22/12	MT
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	28/22/28	MT
Fitch Pulls Vifor Pharma's Rating After CSL Takeover	25/22/25	MT
Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	23/22/23	MT
Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	22/22/22	MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	18/22/18	MT
Australia biotech giant CSL reports profit dip, flags cost spiral	17/22/17	RE
Global markets live: Walt Disney, Bank of America, Sonos, ABB, Roche...	11/22/11
Australia's CSL Closes Vifor Pharma Purchase	11/22/11	MT
CSL Completes Vifor Pharma Acquisition	10/22/10	MT
CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.	09/22/09	CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P Global BMI Index	08/22/08	CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)	08/22/08	CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P EUROPE 350 - Health Care	08/22/08	CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P EUROPE 350	08/22/08	CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P Global 1200	08/22/08	CI
Vifor Pharma AG(SWX:VIFN) dropped from S&P International 700	08/22/08	CI
Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index	05/22/05	CI
Vifor Pharma Announces Resignation of Abbas Hussain as CEO	02/22/02	CI

Chart Vifor Pharma

Duration

Period

More charts

Company Profile

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+13.62%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals